Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.

Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.

SOM Biotech operates as a clinical-stage drug discovery and development company that focuses on the treatment of rare Central Nervous System disorders. The company utilizes an artificial intelligence platform to discover and develop drugs, with emphasis on orphan diseases and repurposing existing drugs for new therapeutic indications. SOM Biotech's lead product has completed Phase 2b trials for Huntington's Disease. It was founded in 2009 and is based in Barcelona, Spain.

Aria Pharmaceuticals operates as a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small-molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using its proprietary symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.

Aitia operates as a biotechnology company. It utilizes causal artificial intelligence (AI), multi-omic patient data, and Gemini Digital Twins to study the biological mechanisms of diseases in the oncology and neurodegenerative disease sectors. The company aims to create computational representations of diseases to assist in the development of therapies. It was founded in 2000 and is based in Somerville, Massachusetts.

Cloud Pharmaceuticals engages in artificial intelligence-based drug discovery and development within the healthcare and technology sectors. The company provides services related to molecule design, preclinical research, optimization, evaluation, and clinical research planning and study design for novel drug compounds. Cloud Pharmaceuticals serves the pharmaceutical, biotechnology, and medical research markets. It is based in Durham, North Carolina.